Author

Vipin Arora

EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Vipin Arora  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Vipin Arora  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Vipin Arora  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Vipin Arora  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Vipin Arora  et al.

PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

Vipin Arora  et al.

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Vipin Arora  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Vipin Arora  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Vipin Arora  et al.

Item 1 - 9 / 9
1